New Blood Test Detects Alzheimer’s Disease by Analyzing Protein Structure

A new blood test offers a potential breakthrough in Alzheimer’s disease diagnosis, moving beyond simply measuring the amount of disease-linked proteins to analyzing their structure. This innovative approach, funded by the National Institutes of Health (NIH), could enable earlier detection, more accurate staging, and improved clinical trials for the devastating neurodegenerative disease.

How the New Blood Test Works

Most current Alzheimer’s blood tests quantify the levels of specific proteins associated with the disease. But, Alzheimer’s disease is characterized by protein misfolding due to disruptions in cellular regulation. This new test focuses on identifying these structural changes in proteins within a blood sample. Researchers used mass spectrometry and machine learning to systematically characterize these structural proteome changes.

Key Findings and Accuracy

The study, published in Nature Aging, identified a diagnostic panel using peptides from C1QA, CLUS, and ApoB, representing Alzheimer’s-associated structural changes. The three-marker panel achieved 83.44% accuracy in distinguishing between healthy individuals, those with mild cognitive impairment (MCI), and those with Alzheimer’s disease.

• Binary classification (healthy vs. MCI) yielded an area under the receiver operating characteristic curve of 0.9343.
• Binary classification (MCI vs. AD) yielded an area under the receiver operating characteristic curve of 0.9325.
• Longitudinal samples were classified with 86.0% accuracy.

Sex Differences and Genetic Risk

The research also provides new insights into how Alzheimer’s disease biology may differ between males and females. By revealing protein structural changes associated with genetic risk, symptom severity, and sex differences, the test could offer a more comprehensive understanding of the disease.

Implications for Diagnosis and Treatment

“This work introduces a fundamentally new, blood-based approach to detecting and staging Alzheimer’s disease,” said Dr. Richard Hodes, director of NIH’s National Institute on Aging. “By revealing protein structural changes associated with genetic risk, symptom severity, and sex differences—features not captured by existing biomarkers—this research could enable earlier diagnosis and more effective clinical trials.”

Existing Blood Tests and the Lumipulse Test

While most Alzheimer’s blood tests measure protein levels, the new approach focuses on protein conformation. The Lumipulse test, recently FDA-approved, measures specific proteins, including a particular form of the tau protein, in a blood sample drawn in a doctor’s office.

Future Directions

This multi-marker panel based on plasma protein structural alterations represents a promising diagnostic approach that may enhance early Alzheimer’s detection and provide insights for clinical trials, ultimately improving therapeutic outcomes. Further research and validation studies are needed to confirm these findings and translate them into widespread clinical use.

Sources:

• National Institutes of Health (NIH): https://www.nih.gov/news-events/news-releases/study-measuring-changes-protein-structure-establishes-new-class-alzheimers-biomarkers
• Nature Aging: https://www.nature.com/articles/s43587-026-01078-2
• PsyPost: https://www.psypost.org/altered-protein-shapes-in-the-blood-can-reveal-early-stages-of-alzheimers-disease/
• Mayo Clinic: https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/new-blood-tests-alzheimers/art-20585060